Cerliponase alfa is a recombinant form of the human lysosomal enzyme tripeptidyl peptidase‑1 (TPP1). It is administered via intracerebroventricular (ICV) infusion and is used as an enzyme replacement therapy for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2 disease), a rare, inherited neurodegenerative disorder characterized by progressive loss of motor and cognitive functions, seizures, and visual decline.
Chemical and Biological Characteristics
- Structure: Cerliponase alfa is a glycosylated protein consisting of 563 amino acids, corresponding to the mature form of human TPP1. It includes N‑linked oligosaccharide chains that facilitate lysosomal targeting.
- Molecular weight: Approximately 69 kDa (including glycosylation).
- Production: Produced in a genetically engineered Chinese hamster ovary (CHO) cell line, followed by purification and formulation for ICV delivery.
Pharmacodynamics
Cerliponase alfa replaces deficient endogenous TPP1 activity in the lysosomes of neuronal cells. TPP1 hydrolyzes small tripeptides from the N‑terminus of substrate proteins, a step essential for normal lysosomal protein degradation. Restoration of TPP1 activity reduces accumulation of autofluorescent lipopigments that characterize CLN2 pathology.
Pharmacokinetics
- Administration route: Continuous ICV infusion via an implanted ventricular access device.
- Distribution: Direct delivery to the cerebrospinal fluid (CSF) bypasses the blood‑brain barrier, achieving therapeutic concentrations throughout the central nervous system.
- Metabolism and elimination: The enzyme is degraded within lysosomes; systemic exposure is minimal.
Medical Use and Clinical Efficacy
Cerliponase alfa received United States Food and Drug Administration (FDA) approval in 2017 under the brand name Brineura (BioMarin Pharmaceutical Inc.) and European Medicines Agency (EMA) approval in 2018. Clinical trials (e.g., the pivotal phase II/III trial) demonstrated that regular ICV administration of cerliponase alfa slowed the decline in motor and language functions compared with the natural disease course, as measured by the CLN2 Clinical Rating Scale.
Safety Profile
Common adverse events observed in clinical studies include:
- Device‑related complications (e.g., infections, catheter obstruction)
- Headache, nausea, vomiting
- Transient fever and irritability
Serious infections related to the ventricular access device have been reported, necessitating aseptic technique and regular monitoring.
Regulatory Status
- United States: FDA-approved as an orphan drug for CLN2 disease.
- European Union: Granted orphan designation and marketing authorization by the EMA.
- Other regions: Approved or under review in several countries with orphan drug frameworks.
Manufacturing and Storage
Cerliponase alfa is supplied as a lyophilized powder for reconstitution. The reconstituted solution must be stored at 2–8 °C and protected from light. Stability data support use within a defined period after preparation.
Research and Development
Ongoing investigations aim to optimize dosing regimens, assess long‑term outcomes, and explore combination therapies with gene‑transfer approaches.
References
- FDA. “Brineura (cerliponase alfa) Prescribing Information,” 2023.
- European Medicines Agency. “Cerliponase alfa Summary of Product Characteristics,” 2022.
- Schulz A, et al. “Long‑term efficacy and safety of intraventricular cerliponase alfa in CLN2 disease,” Neurology, 2021.
All information presented reflects current, peer‑reviewed, and regulatory sources available as of May 2026.